P11 Impact of opiate substitution therapy on hepatitis C treatment oucomes for persons who inject drugs at injecting equipment provision sites in the advance HCV trial
Sign Up to like & getrecommendations! Published in 2020 at "Gut"
DOI: 10.1136/gutjnl-2020-basl.22
Abstract: Background ADVANCE HCV participants are prescribed direct acting anti-viral (DAA) treatment (elbasvir/grazoprevir, ± sofosbuvir for 8/12 weeks) for Hepatitis C (HCV). Eligibility requires participants to be active (within prior 3 months) Persons Who Inject Drugs… read more here.
Keywords: treatment; advance hcv; persons inject; ost prescription ... See more keywords